Molecular Genomics Core

分子基因组学核心

• 批准号: 10333179
• 负责人: Alvaro N Monteiro
• 金额: $ 16.22万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-02-18 至 2027-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10333179
• 关键词: Address; Applications Grants; Automation; Back; Bioinformatics Shared Resource; Biological; Biological Assay; Biometry; Budgets; Cancer Center; Cancer Center Support Grant; Cancer Etiology; Cell Line; Cells; Chromatin; Clinical; Clinical Sciences; Clinical Trials; Consultations; Contracts; Custom; DNA analysis; DNA sequencing; Data; Development; Documentation; Education; Epidemiology; Experimental Designs; Fostering; Funding; Gene Expression; Genome; Genomic approach; Genomics; Genotype; Goals; Head and Neck Squamous Cell Carcinoma; Hematologic Neoplasms; Immune response; Informatics; Institutional Review Boards; Intervention Trial; Journals; Laboratories; Letters; Massive Parallel Sequencing; Mediation; Molecular; Mycoplasma; Neoplasm Metastasis; Peer Review; Performance; Phase; Population; Process; Publications; Quality Control; Reproducibility; Research; Research Activity; Resource Sharing; Sampling; Science; Scientist; Services; Specimen; T-Lymphocyte; Technology; Testing; Therapeutic Studies; Tissues; Training Programs; Training and Education; Transposase; Variant; Vendor; anticancer research; base; cancer genomics; cancer prevention; clinical care; computerized data processing; design; doctoral student; epigenome; epigenomics; experience; experimental study; instrumentation; interest; member; molecular array; molecular pathology; new technology; precision medicine; programs; quality assurance; research study; risk stratification; sample collection; sequencing platform; single cell sequencing; transcriptome; transcriptomics; treatment response; tumor; tumor DNA; tumor heterogeneity; tumor microenvironment

PROJECT SUMMARY MOLECULAR GENOMICS CORE The overarching goal of the Molecular Genomics Core (MGC) is to provide Members with sophisticated genomic, transcriptomic, and epigenomic analysis of bulk and single cell samples to support exceptional, high throughput molecular, biological, epidemiological, and clinical science. MGC is a critical node of a highly integrated Core network with a seamless experimental pipeline with the Tissue Core (TC) and the Biostatistics & Bioinformatics Shared Resource (BBSR). This network provides comprehensive coverage from sample collection through statistical and informatic analysis, with an emphasis on designing highly tailored experiments, including platform choice and analytical approaches. This strategy facilitates informed implementation of precision medicine approaches to meet the research and clinical care needs of Moffitt Members. In support of its goals, MGC activities are organized into three Specific Aims: Aim 1: To provide experimental design consultation services. Aim 2: To provide high quality molecular genomics services. Aim 3: To provide education related to technological advancements in genomics. Over the past cycle, MGC supported 120 Members across all five CCSG Programs, representing a 42% increase in usage since the last renewal and resulting in 101 Member publications (21 in high impact journals) covering broad topics across the cancer research spectrum, including the tumor microenvironment, tumor heterogeneity, immune response to therapy, risk stratification, and circulating tumor DNA analysis. In FY20, MGC supported 54 Members across all five Programs (CBE 32%, CE 20%, MM 22%, HOB 2%, IO 24%), with 95% of those Members holding peer review funding. Overall, MGC successfully supports exceptional research of Members through a highly qualified and experienced staff, state-of-the-art facilities, laboratory automation, a wide array of molecular platforms, and education and training to drive field-leading discoveries in cancer genomics. Over the next five years, MGC will expand and reinforce its repertoire by providing state-of-the-art genomics and transcriptomics services with a focus on expanding the repertoire of single-cell sequencing platforms, developing spatial genomic technology, and automating routine capabilities to meet the current and projected needs of Moffitt Members. To support these endeavors, MGC will also acquire additional platforms and higher-throughput instrumentation. Finally, MGC will also expand its rigor and reproducibility initiatives, as well as its education and training programs for Members and their staff.

项目摘要 分子基因组学核心 分子基因组学核心（MGC）的首要目标是为会员提供复杂的基因组， 批量和单细胞样品的转录组学和表观基因组学分析，以支持卓越的高通量 分子、生物、流行病学和临床科学。MGC是高度集成的核心的关键节点 与组织核心（TC）和生物统计学和生物信息学无缝实验管道网络 共享资源（BBSR）。该网络提供从样本收集到 统计和信息分析，重点是设计高度定制的实验，包括平台 选择和分析方法。这一战略有助于在知情的情况下实施精准医疗 满足莫菲特成员的研究和临床护理需求的方法。为了支持其目标，MGC 活动分为三个具体目标： 目标1：提供实验设计咨询服务。 目标2：提供高质量的分子基因组学服务。 目标3：提供与基因组学技术进步有关的教育。 在过去的一个周期中，MGC在所有五个CCSG计划中支持了120名成员，增长了42 自上一次更新以来，已使用了101种成员出版物（21种在高影响力期刊上）， 癌症研究领域的广泛主题，包括肿瘤微环境，肿瘤异质性， 对治疗的免疫应答、危险分层和循环肿瘤DNA分析。20财年，MGC支持 54名成员参加了所有五个项目（CBE 32%，CE 20%，MM 22%，HOB 2%，IO 24%），其中95%的成员 拥有同行评审资金的成员。总体而言，MGC成功地支持了会员的卓越研究 通过高素质且经验丰富的员工、最先进的设施、实验室自动化、各种 分子平台，教育和培训，以推动癌症基因组学领域的领先发现。 在接下来的五年里，MGC将通过提供最先进的基因组学和 转录组学服务，重点是扩大单细胞测序平台的库，开发 空间基因组技术，以及自动化常规能力，以满足当前和预计的需求， 莫菲特成员。为了支持这些努力，MGC还将获得更多的平台和更高的吞吐量 仪器仪表最后，MGC还将扩大其严谨性和可重复性举措，以及教育和 为会员及其工作人员提供培训。